Committee Member | Present | Absent |
---|---|---|
X | ||
X | ||
X | ||
X | ||
X | ||
Debbie Knapp | X | |
Toby Hecht | X | |
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Item | Who | Talking Points |
---|---|---|
DGAB Updates |
| |
BPSC Updates |
| |
November Steering Committee Updates |
| |
ICDC Next Phase Planning |
|
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
TH - Circulating tumor DNA is a strong candidate for the next phase of the ICDC.
CS - There is a grant under the mammalian models from Cheryl London and co.
Action items